Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling results from its latest pre-pivotal clinical trial for its next-generation continuous glucose monitoring (CGM) system.
Trinity stock is trading higher on Tuesday after the company announced results from its pre-pivotal clinical trial for its ...
Shares of Trinity Biotech climbed after the company released what it called compelling results from a study of its next-generation continuous glucose monitoring system, a device used for diabetes ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback